




W E B I N A R

THE
NEW 4-WEEKS DOSING OPTION

**FOR PEGUNIGALSIDASE ALFA:
CLINICAL EVIDENCE
AND PRACTICAL CONSIDERATIONS**



NON-CME WEBINAR:

THE NEW 4-WEEKS DOSING OPTION FOR PEGUNIGALSIDASE ALFA: CLINICAL EVIDENCE AND PRACTICAL CONSIDERATIONS

1. SmPC changes and key updates | 15'

Speaker: **Prof. A. Linhart**

Content focus:

Overview of SmPC updates related to the E4W dosing regimen, including the additional PK/PD data.

2. Practical considerations from the SmPC | 15'

Speaker: **Prof. A. Linhart**

Content focus

- Practical aspects derived from SmPC information (e.g., infusion details, management considerations)
- Stability concept
- Monitoring examples
- Renal impairment considerations

3. BRIGHT and F51 studies: evidence on E4W dosing | 30'

Speaker: **Prof. A. Linhart**

4. Practical management of patients treated with pegunigalsidase alfa | 30'

Speaker: **Dr. G. Dostálová**

Content focus

- Flexibility of dosing options (E2W and E4W) and how they support personalized treatment pathways with pegunigalsidase alfa
- Real-world operational aspects of managing E2W and E4W infusion schedules